Cart
sales@molnova.com
Fallypride
CAS No. 166173-78-0
Fallypride( —— )
Catalog No. M36336 CAS No. 166173-78-0
Fallypride is a potent and selective dopamine D2/D3 receptor antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 676 | In Stock |
|
| 5MG | 842 | In Stock |
|
| 10MG | 1036 | In Stock |
|
| 25MG | 1663 | In Stock |
|
| 50MG | 2027 | In Stock |
|
| 100MG | 2604 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFallypride
-
NoteResearch use only, not for human use.
-
Brief DescriptionFallypride is a potent and selective dopamine D2/D3 receptor antagonist.
-
DescriptionFallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride (18F), can be used as a positron emission tomography (PET) radiotracer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number166173-78-0
-
Formula Weight364.45
-
Molecular FormulaC20H29FN2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NC[C@H]1N(CC=C)CCC1)(=O)C2=C(OC)C(OC)=CC(CCCF)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. J Mukherjee, wt al. Fluorinated benzamide neuroleptics—III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995 Apr;22(3):283-96.?
molnova catalog
related products
-
BP-897
BP-897 is the first, potent, selective partial dopamine D3 receptor agonist with Ki of 0.92 nM.
-
Fipexide
Fipexide (Attentil, Vigilor) is a psychoactive drug of the piperazine chemical class which was developed in Italy in 1983.
-
Nolomirole HCl
Nolomirole HCl (CHF 1035) is a novel selective dopamine agonist with oral activity and inhibitory effects on norepinephrine release, which can be used to study mild chronic heart failure.
